Literature DB >> 22508931

IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells.

Benjamin M Matta1, Giorgio Raimondi, Brian R Rosborough, Tina L Sumpter, Angus W Thomson.   

Abstract

Plasmacytoid dendritic cells (pDCs) are highly specialized APCs that, in addition to their well-recognized role in anti-viral immunity, also regulate immune responses. Liver-resident pDCs are considerably less immunostimulatory than those from secondary lymphoid tissues and are equipped to promote immune tolerance/regulation through various mechanisms. IL-27 is an IL-12 family cytokine that regulates the function of both APCs and T cells, although little is known about its role in pDC immunobiology. In this study, we show that mouse liver pDCs express higher levels of IL-27p28 and EBV-induced protein 3 (Ebi3) compared with those of splenic pDCs. Both populations of pDCs express the IL-27Rα/WSX-1; however, only liver pDCs significantly upregulate expression of the coregulatory molecule B7 homolog-1 (B7-H1) in response to IL-27. Inhibition of STAT3 activation completely abrogates IL-27-induced upregulation of B7-H1 expression on liver pDCs. Liver pDCs treated with IL-27 increase the percentage of CD4(+)Foxp3(+) T cells in MLR, which is dependent upon expression of B7-H1. pDCs from Ebi3-deficient mice lacking functional IL-27 show increased capacity to stimulate allogeneic T cell proliferation and IFN-γ production in MLR. Liver but not spleen pDCs suppress delayed-type hypersensitivity responses to OVA, an effect that is lost with Ebi3(-/-) and B7-H1(-/-) liver pDCs compared with wild-type liver pDCs. These data suggest that IL-27 signaling in pDCs promotes their immunoregulatory function and that IL-27 produced by pDCs contributes to their capacity to regulate immune responses in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508931      PMCID: PMC3564546          DOI: 10.4049/jimmunol.1103382

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

Review 1.  Anatomical basis of tolerance and immunity to intestinal antigens.

Authors:  Allan McI Mowat
Journal:  Nat Rev Immunol       Date:  2003-04       Impact factor: 53.106

2.  Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment.

Authors:  Atsunobu Takeda; Shinjiro Hamano; Atsushi Yamanaka; Toshikatsu Hanada; Tatsuro Ishibashi; Tak W Mak; Akihiko Yoshimura; Hiroki Yoshida
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

3.  WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27.

Authors:  Stefan Pflanz; Linda Hibbert; Jeanine Mattson; Rency Rosales; Elena Vaisberg; J Fernando Bazan; Joseph H Phillips; Terrill K McClanahan; Rene de Waal Malefyt; Robert A Kastelein
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

4.  Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition.

Authors:  Venu G Pillarisetty; Alaap B Shah; George Miller; Joshua I Bleier; Ronald P DeMatteo
Journal:  J Immunol       Date:  2004-01-15       Impact factor: 5.422

Review 5.  Tolerogenic plasmacytoid DC.

Authors:  Benjamin M Matta; Antonino Castellaneta; Angus W Thomson
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

6.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.

Authors:  Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

7.  Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.

Authors:  Julia A Brown; David M Dorfman; Feng-Rong Ma; Elizabeth L Sullivan; Oliver Munoz; Clive R Wood; Edward A Greenfield; Gordon J Freeman
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

8.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

9.  A role for IL-27p28 as an antagonist of gp130-mediated signaling.

Authors:  Jason S Stumhofer; Elia D Tait; William J Quinn; Nancy Hosken; Björn Spudy; Radhika Goenka; Ceri A Fielding; Aisling C O'Hara; Yi Chen; Michael L Jones; Christiaan J M Saris; Stefan Rose-John; Daniel J Cua; Simon A Jones; Merle M Elloso; Joachim Grötzinger; Michael P Cancro; Steven D Levin; Christopher A Hunter
Journal:  Nat Immunol       Date:  2010-11-07       Impact factor: 25.606

Review 10.  Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27.

Authors:  Alejandro V Villarino; Christopher A Hunter
Journal:  Arthritis Res Ther       Date:  2004-08-16       Impact factor: 5.156

View more
  51 in total

1.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

2.  PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.

Authors:  Ozlen Saglam; Jose Conejo-Garcia
Journal:  Integr Cancer Sci Ther       Date:  2018-04-14

3.  Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Authors:  Lisa K Spary; Josephine Salimu; Jason P Webber; Aled Clayton; Malcolm D Mason; Zsuzsanna Tabi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 4.  Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells.

Authors:  Jessica Bourque; Daniel Hawiger
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

Review 5.  Regulation and Function of the PD-L1 Checkpoint.

Authors:  Chong Sun; Riccardo Mezzadra; Ton N Schumacher
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

6.  DAP12 deficiency in liver allografts results in enhanced donor DC migration, augmented effector T cell responses and abrogation of transplant tolerance.

Authors:  O Yoshida; S Kimura; L Dou; B M Matta; S Yokota; M A Ross; D A Geller; A W Thomson
Journal:  Am J Transplant       Date:  2014-06-16       Impact factor: 8.086

Review 7.  Plasmacytoid dendritic cells: no longer an enigma and now key to transplant tolerance?

Authors:  N M Rogers; J S Isenberg; A W Thomson
Journal:  Am J Transplant       Date:  2013-04-25       Impact factor: 8.086

8.  Efficacy of azithromycin in preventing lethal graft-versus-host disease.

Authors:  S Iwamoto; E Azuma; T Kumamoto; M Hirayama; T Yoshida; M Ito; K Amano; M Ido; Y Komada
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

9.  Plasmacytoid dendritic cell-derived IFN-α promotes murine liver ischemia/reperfusion injury by induction of hepatocyte IRF-1.

Authors:  Antonino Castellaneta; Osamu Yoshida; Shoko Kimura; Shinichiro Yokota; David A Geller; Noriko Murase; Angus W Thomson
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

10.  CD39 expression by hepatic myeloid dendritic cells attenuates inflammation in liver transplant ischemia-reperfusion injury in mice.

Authors:  Osamu Yoshida; Shoko Kimura; Edwin K Jackson; Simon C Robson; David A Geller; Noriko Murase; Angus W Thomson
Journal:  Hepatology       Date:  2013-10-15       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.